FOXM1 and HER2 in Breast Cancer
Author Information
Author(s): Bektas Nuran, Haaf Anette ten, Veeck Jürgen, Wild Peter Johannes, Lüscher-Firzlaff Juliane, Hartmann Arndt, Knüchel Ruth, Dahl Edgar
Primary Institution: Institute of Pathology, University Hospital of the RWTH Aachen
Hypothesis
Is there a correlation between FOXM1 expression and HER2 status in breast cancer?
Conclusion
FOXM1 may serve as a new breast tumor marker with prognostic significance and a potential drug target in HER2 resistant breast tumors.
Supporting Evidence
- FOXM1 was overexpressed in breast cancer compared to normal breast tissue.
- A significant correlation was found between FOXM1 expression and HER2 status.
- 87% of breast carcinomas expressed nuclear FOXM1 compared to 42% of normal breast tissues.
- Patients with nuclear FOXM1 expression showed a tendency towards unfavourable prognosis.
Takeaway
This study found that a protein called FOXM1 is more common in breast cancer than in normal breast tissue, and it might help doctors understand how to treat some breast cancers better.
Methodology
The study used immunohistochemistry and semiquantitative realtime PCR to analyze FOXM1 expression in breast cancer and normal tissues.
Potential Biases
Potential biases may arise from the selection of tissue samples and the retrospective nature of the study.
Limitations
The study is based on retrospective data and may not account for all variables affecting patient outcomes.
Participant Demographics
Patients' ages ranged from 25 to 82 years, with a median age of 56 years.
Statistical Information
P-Value
0.045
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website